InflaRx (IFRX) Fundamentals 2026 — Revenue Analysis | SniperIQ
InflaRx (IFRX) is a DE-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is InflaRx's market cap?
InflaRx (IFRX) has a market capitalization of approximately
What is InflaRx's P/E ratio?
InflaRx's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is InflaRx?
InflaRx runs a net profit margin of -146303.9%, a gross margin of -24646.3%, and an operating margin of -144445.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does InflaRx generate?
InflaRx reported revenue of €29,331 for fiscal year 2025, with net income of -€46M and earnings per share (EPS) of -0.66. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does InflaRx pay a dividend?
InflaRx does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is InflaRx financially healthy?
InflaRx carries a debt-to-equity ratio of 0.02x and a current ratio of 4.16x, with a market beta of 2.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is InflaRx a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For InflaRx (IFRX) the key facts are: market cap
Track InflaRx's full fundamentals live
Get InflaRx's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.